Skip to main content
Top
Published in: Hepatology International 2/2021

01-04-2021 | Liver Resection | Original Article

Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study

Authors: Lei Liang, Bing Quan, Han Wu, Yong-Kang Diao, Jie Li, Ting-Hao Chen, Yao-Ming Zhang, Ya-Hao Zhou, Wan-Guang Zhang, Hong Wang, Matteo Serenari, Matteo Cescon, Myron Schwartz, Yong-Yi Zeng, Ying-Jian Liang, Hang-Dong Jia, Hao Xing, Chao Li, Ming-Da Wang, Wen-Tao Yan, Wan-Yuan Chen, Wan Yee Lau, Cheng-Wu Zhang, Timothy M. Pawlik, Dong-Sheng Huang, Feng Shen, Tian Yang

Published in: Hepatology International | Issue 2/2021

Login to get access

Abstract

Background

Evidence-based decision-making is critical to optimize the benefits and mitigate futility associated with surgery for patients with malignancies. Untreated hepatocellular carcinoma (HCC) has a median survival of only 6 months. The objective was to develop and validate an individualized patient-specific tool to predict preoperatively the benefit of surgery to provide a survival benefit of at least 6 months following resection.

Methods

Using an international multicenter database, patients who underwent curative-intent liver resection for HCC from 2008 to 2017 were identified. Using random assignment, two-thirds of patients were assigned to a training cohort with the remaining one-third assigned to the validation cohort. Independent predictors of postoperative death within 6 months after surgery for HCC were identified and used to construct a nomogram model with a corresponding online calculator. The predictive accuracy of the calculator was assessed using C-index and calibration curves.

Results

Independent factors associated with death within 6 months of surgery included age, Child–Pugh grading, portal hypertension, alpha-fetoprotein level, tumor rupture, tumor size, tumor number and gross vascular invasion. A nomogram that incorporated these factors demonstrated excellent calibration and good performance in both the training and validation cohorts (C-indexes: 0.802 and 0.798). The nomogram also performed better than four other commonly-used HCC staging systems (C-indexes: 0.800 vs. 0.542–0.748).

Conclusions

An easy-to-use online prediction calculator was able to identify patients at highest risk of death within 6 months of surgery for HCC. The proposed online calculator may help guide surgical decision-making to avoid futile surgery for patients with HCC.
Literature
1.
go back to reference Wilson A, Ronnekleiv-Kelly SM, Pawlik TM. Regret in surgical decision making: a systematic review of patient and physician perspectives. World J Surg 2017;41:1454–1465PubMedCrossRef Wilson A, Ronnekleiv-Kelly SM, Pawlik TM. Regret in surgical decision making: a systematic review of patient and physician perspectives. World J Surg 2017;41:1454–1465PubMedCrossRef
2.
go back to reference Robson N, Rew D. Collective wisdom and decision making in surgical oncology. Eur J Surg Oncol 2010;36:230–236PubMedCrossRef Robson N, Rew D. Collective wisdom and decision making in surgical oncology. Eur J Surg Oncol 2010;36:230–236PubMedCrossRef
3.
go back to reference Lamb B, Green JS, Vincent C, et al. Decision making in surgical oncology. Surg Oncol 2011;20:163–8PubMedCrossRef Lamb B, Green JS, Vincent C, et al. Decision making in surgical oncology. Surg Oncol 2011;20:163–8PubMedCrossRef
5.
go back to reference Nagasue N, Yukaya H, Hamada T, et al. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 1984;54:1461–1465PubMedCrossRef Nagasue N, Yukaya H, Hamada T, et al. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 1984;54:1461–1465PubMedCrossRef
6.
go back to reference Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–928PubMedCrossRef Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–928PubMedCrossRef
7.
go back to reference Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34PubMedCrossRef Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34PubMedCrossRef
8.
go back to reference Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390PubMedCrossRef Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390PubMedCrossRef
9.
go back to reference Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol 2015;33:1835–1844PubMedCrossRef Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol 2015;33:1835–1844PubMedCrossRef
10.
go back to reference Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156(477–491):e1 Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156(477–491):e1
11.
go back to reference Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011;253:453–469PubMedCrossRef Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011;253:453–469PubMedCrossRef
12.
go back to reference Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004;127:S248-S260PubMedCrossRef Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004;127:S248-S260PubMedCrossRef
13.
go back to reference Liu J, Zhang H, Xia Y, et al. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2019;21:1–13CrossRef Liu J, Zhang H, Xia Y, et al. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2019;21:1–13CrossRef
14.
go back to reference Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol 2020;72:75–84PubMedCrossRef Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol 2020;72:75–84PubMedCrossRef
15.
go back to reference Vitale A, Burra P, Frigo AC, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol 2015;62:617–624PubMedCrossRef Vitale A, Burra P, Frigo AC, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol 2015;62:617–624PubMedCrossRef
16.
go back to reference Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61:583–588PubMedCrossRef Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61:583–588PubMedCrossRef
17.
go back to reference Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137:403–10PubMedCrossRef Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137:403–10PubMedCrossRef
18.
go back to reference Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 2016;65:938–943PubMedCrossRef Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 2016;65:938–943PubMedCrossRef
19.
go back to reference Dhir M, Melin AA, Douaiher J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 2016;263:1112–1125PubMedCrossRef Dhir M, Melin AA, Douaiher J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 2016;263:1112–1125PubMedCrossRef
20.
go back to reference Yang T, Lu JH, Lau WY, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a propensity score matching analysis. J Hepatol 2016;64:583–593PubMedCrossRef Yang T, Lu JH, Lau WY, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a propensity score matching analysis. J Hepatol 2016;64:583–593PubMedCrossRef
21.
go back to reference Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg 2019;154:209–217PubMedCrossRef Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg 2019;154:209–217PubMedCrossRef
22.
go back to reference Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. Br J Surg. 2019;106:1228–1236PubMedCrossRef Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. Br J Surg. 2019;106:1228–1236PubMedCrossRef
23.
go back to reference Wang MD, Li C, Li J, et al. Long-term survival outcomes after liver resection for binodular hepatocellular carcinoma: a multicenter cohort study. Oncologist 2019;24:e730–e739PubMedPubMedCentralCrossRef Wang MD, Li C, Li J, et al. Long-term survival outcomes after liver resection for binodular hepatocellular carcinoma: a multicenter cohort study. Oncologist 2019;24:e730–e739PubMedPubMedCentralCrossRef
25.
go back to reference Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol 2018;37:481–491PubMedCrossRef Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol 2018;37:481–491PubMedCrossRef
27.
go back to reference Kerr KF, Brown MD, Zhu K, et al. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol 2016;34:2534–40PubMedPubMedCentralCrossRef Kerr KF, Brown MD, Zhu K, et al. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol 2016;34:2534–40PubMedPubMedCentralCrossRef
28.
go back to reference Dasari B, Hodson J, Sutcliffe RP, et al. Developing and validating a preoperative risk score to predict 90-day mortality after liver resection. J Surg Oncol 2019;119:472–478PubMedCrossRef Dasari B, Hodson J, Sutcliffe RP, et al. Developing and validating a preoperative risk score to predict 90-day mortality after liver resection. J Surg Oncol 2019;119:472–478PubMedCrossRef
29.
go back to reference Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 2015;261:939–946PubMedCrossRef Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 2015;261:939–946PubMedCrossRef
30.
go back to reference Yang P, Qiu J, Li J, et al. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg 2016;263:778–786PubMedCrossRef Yang P, Qiu J, Li J, et al. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg 2016;263:778–786PubMedCrossRef
31.
go back to reference Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020;72:215–229PubMedCrossRef Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020;72:215–229PubMedCrossRef
32.
go back to reference Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020 Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020
33.
go back to reference Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006;141:191–8PubMedCrossRef Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006;141:191–8PubMedCrossRef
34.
go back to reference Yang T, Sun YF, Zhang J, et al. Partial hepatectomy for ruptured hepatocellular carcinoma. Br J Surg 2013;100:1071–1079PubMedCrossRef Yang T, Sun YF, Zhang J, et al. Partial hepatectomy for ruptured hepatocellular carcinoma. Br J Surg 2013;100:1071–1079PubMedCrossRef
35.
go back to reference Moris D, Chakedis J, Sun SH, et al. Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review. J Surg Oncol 2018;117:341–353PubMedCrossRef Moris D, Chakedis J, Sun SH, et al. Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review. J Surg Oncol 2018;117:341–353PubMedCrossRef
36.
go back to reference Glantzounis GK, Tokidis E, Basourakos SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017;43:32–41PubMedCrossRef Glantzounis GK, Tokidis E, Basourakos SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017;43:32–41PubMedCrossRef
37.
go back to reference Song T. Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discov Ther. 2015;9:319–330PubMedCrossRef Song T. Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discov Ther. 2015;9:319–330PubMedCrossRef
38.
go back to reference Raptis DA, Linecker M, Kambakamba P, et al. Defining benchmark outcomes for ALPPS. Ann Surg 2019;270:835–841PubMedCrossRef Raptis DA, Linecker M, Kambakamba P, et al. Defining benchmark outcomes for ALPPS. Ann Surg 2019;270:835–841PubMedCrossRef
39.
go back to reference Olthof PB, Schnitzbauer AA, Schadde E. The HPB controversy of the decade: 2007–2017 - ten years of ALPPS. Eur J Surg Oncol 2018;44:1624–1627PubMedCrossRef Olthof PB, Schnitzbauer AA, Schadde E. The HPB controversy of the decade: 2007–2017 - ten years of ALPPS. Eur J Surg Oncol 2018;44:1624–1627PubMedCrossRef
40.
go back to reference Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66:510–517PubMedCrossRef Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66:510–517PubMedCrossRef
41.
go back to reference Liang L, Chen TH, Li C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford) 2018;20:1119–1129CrossRef Liang L, Chen TH, Li C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford) 2018;20:1119–1129CrossRef
43.
go back to reference Morris AM. Rational vs. intuitive judgment in surgical decision making. Ann Surg 2016;264:887–888PubMedCrossRef Morris AM. Rational vs. intuitive judgment in surgical decision making. Ann Surg 2016;264:887–888PubMedCrossRef
Metadata
Title
Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study
Authors
Lei Liang
Bing Quan
Han Wu
Yong-Kang Diao
Jie Li
Ting-Hao Chen
Yao-Ming Zhang
Ya-Hao Zhou
Wan-Guang Zhang
Hong Wang
Matteo Serenari
Matteo Cescon
Myron Schwartz
Yong-Yi Zeng
Ying-Jian Liang
Hang-Dong Jia
Hao Xing
Chao Li
Ming-Da Wang
Wen-Tao Yan
Wan-Yuan Chen
Wan Yee Lau
Cheng-Wu Zhang
Timothy M. Pawlik
Dong-Sheng Huang
Feng Shen
Tian Yang
Publication date
01-04-2021
Publisher
Springer India
Published in
Hepatology International / Issue 2/2021
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10140-7

Other articles of this Issue 2/2021

Hepatology International 2/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.